PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma By Ogkologos - February 9, 2026 47 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PACT-21 CASSANDRA study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR FDA Grants Accelerated Approval to Tovorafenib for Patients with Relapsed or... May 2, 2024 A Better Biomarker for Cancer Immunotherapy? November 3, 2023 FDA Approves Azacitidine Tablets for Acute Myeloid Leukaemia September 4, 2020 EMA Recommends Granting a Conditional Marketing Authorisation for Avapritinib July 28, 2020 Load more HOT NEWS Adjuvant Imatinib Prolongs RFS and OS in Patients with Resected GIST... Five Questions With…Jim. Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α Can Getting a “Base Tan” Protect You From Sunburn and Skin...
